Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

about

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

Item

http://www.wikidata.org/entity/Q42286651

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

@en

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

@nl

type

Item

label

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

@en

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

@nl

prefLabel

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

@en

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

@nl

P1476

Malignant Retroperitoneal Extra-Gastrointestinal Stromal Tumor: A Unique Entity.

@en

P2093

Archana Rastogi

http://www.w3.org/2001/XMLSchema#string

Shalini Thapar Laroia

http://www.w3.org/2001/XMLSchema#string

Shiv Sarin

http://www.w3.org/2001/XMLSchema#string

Taruna Yadav

http://www.w3.org/2001/XMLSchema#string

P2860

Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004.

Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.

Gastrointestinal stromal tumour of small intestine presenting as a mesenteric mass.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Retroperitoneal extragastrointestinal stromal tumor: radiologic pathologic correlation

Pancreatic extragastrointestinal stromal tumor: A case report and comprehensive literature review.

Prediction of Tumor Recurrence in Patients with Non-Gastric Gastrointestinal Stromal Tumors Following Resection according to the Modified National Institutes of Health Criteria.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Primary retroperitoneal neoplasms: CT and MR imaging findings with anatomic and pathologic diagnostic clues.

P304

45-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.14740/WJON926W

http://www.w3.org/2001/XMLSchema#string

P433

2-3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28983363

http://www.w3.org/2001/XMLSchema#string

P932

5624696

http://www.w3.org/2001/XMLSchema#string